Setmelanotide: Who Lost Weight in Trials?

The population behind the percentage

Setmelanotide targets the melanocortin-4 receptor pathway, which contributes to appetite and body-weight regulation. The pivotal 2020 report studied people with severe obesity caused by POMC or LEPR deficiency. These were selected genetic conditions, not a broad sample of people seeking weight loss. Their biology is central to interpreting the results ^[1].

At approximately one year, eight of ten participants in the POMC trial and five of eleven in the LEPR trial had lost at least 10 percent of their initial weight. Those are responder proportions: 80 percent and 45 percent of two small groups. They do not mean that participants lost 80 percent or 45 percent of their body weight ^[1].

The study design

The trials were primarily single-arm and open-label. Participants who lost enough weight in an initial treatment phase entered a blinded withdrawal sequence, followed by further open-label treatment. That structure gives information about treatment response and withdrawal, but it is different from maintaining parallel drug and placebo groups for an entire year ^[1].

Hunger improvements were assessed in a subset meeting age and initial-response criteria. The published hunger percentages therefore have a different denominator from the overall weight-response counts. Combining them into one universal expectation would erase the selection rules that shaped the analysis ^[1].

Bardet-Biedl and Alström syndromes

A subsequent study enrolled 38 participants with Bardet-Biedl or Alström syndrome. It began with 14 weeks of randomized double-blind treatment and then continued into an open-label period. Among participants aged at least twelve with Bardet-Biedl syndrome, 32.3 percent reached a weight reduction of at least 10 percent after 52 weeks of setmelanotide ^[2].

The investigators reported the Alström syndrome findings as inconclusive. A shared pathway hypothesis did not justify treating the two syndromes as interchangeable evidence. The trial also illustrates why the initial randomized phase and the later one-year responder endpoint should be described separately ^[2].

Benefits alongside adverse effects

Injection-site reactions and changes in skin pigmentation were prominent in these reports. All ten participants in the POMC trial reported injection-site reactions and hyperpigmentation. In the later syndrome trial, hyperpigmentation occurred in 23 of 38 participants and injection-site redness in 18. Small samples and limited follow-up cannot resolve every uncommon or long-term risk ^{[1, 2]}.

The useful question is whether a person has the disorder studied and meets the current product indication, not whether setmelanotide belongs on a generic ranking of weight-loss peptides. The setmelanotide monograph keeps the label and other studies together; the weight-loss evidence comparison distinguishes the wider group.

Elsewhere in this index